Eric Wintemute
Analyst · SunTrust Robinson Humphrey. Please proceed with your question
Thank you, David. Now let's turn to several key initiatives that we are pursuing. American Vanguard has grown substantially over the last 25 years by acquiring or licensing established niche products, equipment systems and manufacturing facilities. Today we continue that pursuit. In 2015, we acquired two products from DuPont, one from Adama and licensed one for BASF while still improving our cash position and borrowing capacity. In 2016, we are reviewing several additional possibilities and with the debt-to-equity ratio of under 0.25 we are on a strong position to acquire or license such products going forward. Additionally, we have invested in several paths for new product development with our ownership position in the natural oil, technology of Envance and more recently our equity position in the European Research and Commercial Development firm Bi Pa. Over the course of the next several years, we are looking forward to commercializing throughout the Americas both in existing Biba fungicides for fruits and vegetable crops as well as other biological products from their pipeline. We also anticipate potential technology benefits from our relationships with other key international partners. We've been building our global presence significantly over the last five years starting with doubling of our international sales in 2011 following the acquisition of Mocap and Nemacur in insecticides from Bayer Crop Science. In 2012, we established a wholly owned subsidiary in the Netherlands to exclusively manage our non US business. And staff this operating unit with highly experienced personnel. Over the last year, several key executives have jointed American Vanguard, each of whom has extensive global credentials. AMVAC CEO [Obancha Gill] is pursuing several market access and technology initiatives which will expand our world by present. Our new Head of Global Marketing and Commercial Development, Peter Ehlers and our new director of business development, Martin Peterson is also contributing to these efforts. And just this past week we announced the establishment of an operating unit in Asia Pacific region based in Singapore managed by another prominent new hire Lawrence Yu. Lawrence will spearhead a number of collaborative partnerships that we've exploring in Asia which will allow us to participate and enhancing agriculture productivity in this growing region. Next, I'd like to comment on the development of our precision Ag equivalent technology. Over the last year we've spoken about our initiative to transform and broaden the existing smart box granular insecticides delivery system into a more comprehensive multi product, yield enhancing, at planting time, treatment system. This system is capable of dispensing the precise amount of crop protection or plant nutrient to optimize crop yield. It will be the technology that enables an agronomous prescription to be applied to a particular field in a single pass. Much as an inkjet printer paints an intended image on paper, Simpass will paint the field with just the right dosage of inputs to maximize yield and profitability for the grower. I can tell you we are making significant progress and a plan on providing greater detail at our annual shareholders conference call scheduled for June 8. Finally, let me address our mosquito control business. Recently there has been considerable concern about the rapid global spread of the Zika virus and various mosquito control method to limit this disease. There are many approaches used for mosquito control including larvicide, , ground level chemical fogging and aerial applications of adulticide for comprehensive wide area coverage. AMVAC is an exclusive producer of Dibrom, the most effective product for such aerial applications. Since Dibrom has been used more selectively than other products, the potential for developing mosquito resistance to Dibrom remains low. Dibrom is relatively odorless and highly effective and is the preferred choice among aerial applicators. In light of the Zika virus threat and many other mosquito borne diseases such as West Nile and Dengue fever, we expect our Dibrom product will experience increase in the future. We also exploring the expansion of our mosquito control product line with additional larvicide, biological and natural oil chemical combinations. Going forward, we will borrow from --word from us last year. Control operating expenses, inventory and manufacturing costs through financial discipline. Acquire license accretive products for managing cash and optimizing borrower capacity. And continuing to invest in precision Ag technology, international expansion and top managerial talent. We believe that these are the elements of our future success. And with that we'll be happy to entertain any questions you have. Kevin?